Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
83.82
Nov 13 • 3:59 PM ET Dollar change+0.86 Percentage change(1.04%)
Aftermarket Close
83.76
Aftermarket • 7:44 PM ET Dollar change-0.06 Percentage change(-0.07%)
Index
S&P 500, RUI
Market Cap
34.06B
Enterprise Value
41.76B
Income
2.49B
Sales
9.51B
Book/sh
8.11
Cash/sh
3.77
Employees
14500
IPO
Feb 01, 2013
P/E
14.24
Forward P/E
13.28
PEG
8.20
P/S
3.58
P/B
10.34
P/C
22.22
P/FCF
14.95
EV/EBITDA
10.36
EV/Sales
4.39
Quick Ratio
1.40
Current Ratio
2.35
Debt/Eq
2.80
LT Debt/Eq
2.57
Option/Short
Yes / Yes
EPS (ttm)
5.89
EPS next Y
6.31
EPS next Q
1.21
EPS this Y
-1.57%
EPS next Y
0.00%
EPS next 5Y
1.62%
EPS past 3/5Y
10.25% 11.96%
Sales past 3/5Y
5.42% 7.24%
EPS Y/Y TTM
-0.84%
Sales Y/Y TTM
1.18%
EPS Q/Q
-11.73%
Sales Q/Q
-0.38%
Insider Own
0.23%
Insider Trans
0.00%
Inst Own
104.55%
Inst Trans
-2.62%
ROA
16.44%
ROE
57.14%
ROIC
21.09%
Gross Margin
70.05%
Oper. Margin
37.37%
Profit Margin
26.15%
SMA20
2.92%
SMA50
9.87%
SMA200
-8.38%
Trades
Shs Outstand
407.49M
Shs Float
405.38M
52W High
132.49 -36.73%
52W Low
68.77 21.88%
Volatility
2.64% 2.83%
ATR (14)
2.54
RSI (14)
58.87
Beta
0.67
Rel Volume
0.69
Avg Volume
4.60M
Volume
3,152,494
Perf Week
5.57%
Perf Month
6.89%
Perf Quarter
14.87%
Perf Half Y
12.93%
Perf YTD
-33.38%
Perf Year
-30.82%
Perf 3Y
-50.35%
Perf 5Y
-61.35%
Perf 10Y
65.62%
Prev Close
82.96
Price
83.82
Change %
1.04%
Consensus
Buy
Avg. Price Target
$88.55
Implied Upside
+5.6%
Analysts15incl. previous ratings
Rating Distribution5 Buy · 10 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 20, 2026Downgrade
JEF logoJJefferies
Buy → Hold$83-1.0%
Oct 16, 2026Initiated
GS logoGGoldman
Neutral$74-11.7%
Aug 06, 2026Downgrade
WWilliam Blair
Outperform → Mkt Perform
May 27, 2026Downgrade
AArgus
Buy → Hold
Apr 15, 2026Initiated
C logoCCitigroup
Buy$145+73.0%
Jan 22, 2026Downgrade
PPiper Sandler
Overweight → Neutral$135+61.1%
Dec 15, 2025Downgrade
BAC logoBBofA Securities
Buy → Neutral$135+61.1%
Dec 09, 2025Initiated
BCS logoBBarclays
Equal Weight$136+62.3%
Nov 21, 2025Initiated
KEY logoKKeyBanc Capital Markets
Sector Weight
Jul 17, 2025Downgrade
LLeerink Partners
Outperform → Market Perform$155+84.9%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DAMELIO FRANK ADirectorMay 13 '26Buy75.396,650501,34421,458May 13 04:35 PM
Bisaro PaulDirectorMay 13 '26Buy75.882,000151,75027,862May 13 04:35 PM
MCCALLISTER MICHAEL BDirectorMay 11 '26Buy77.763,000233,27324,524May 12 07:26 PM
PECK KRISTIN CChief Executive OfficerFeb 17 '26Option Exercise41.8320,000836,600121,337Feb 17 04:22 PM
PECK KRISTIN CChief Executive OfficerFeb 17 '26Sale127.0520,0002,540,964101,337Feb 17 04:22 PM
Polzer Robert JOfficerFeb 17 '26Proposed Sale127.342,346298,742Feb 17 04:14 PM
PECK KRISTIN COfficerFeb 17 '26Proposed Sale127.0520,0002,540,964Feb 17 04:13 PM
Polzer Robert JOfficerFeb 13 '26Proposed Sale129.093,662472,728Feb 13 04:26 PM
Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. It operates through the United States and International geographical segments. The company was founded in 1952 and is headquartered in Parsippany, NJ.
CEO & DirectorMs. Kristin C. Peck
Executive VPMs. Roxanne Lagano
Scientific AdvisorDr. Robert J. Polzer Ph.D.
Executive VP & Chief Commercial OfficerMr. Jamie Brannan
Executive VPMr. James K. Saccaro